Sergey Viktorovich Kozin, D.Sc.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 9 | 2015 | 2634 | 0.540 |
Why?
|
| Chlorambucil | 3 | 2006 | 42 | 0.500 |
Why?
|
| Radiosurgery | 1 | 2022 | 1346 | 0.410 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2015 | 506 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 3 | 2001 | 419 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2007 | 550 | 0.330 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2006 | 2488 | 0.320 |
Why?
|
| Endothelial Cells | 3 | 2012 | 3591 | 0.240 |
Why?
|
| Radium | 1 | 2024 | 70 | 0.210 |
Why?
|
| Veratrum | 1 | 2022 | 1 | 0.210 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 9213 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 9264 | 0.200 |
Why?
|
| Tibia | 1 | 2008 | 1076 | 0.200 |
Why?
|
| Lung Neoplasms | 6 | 2010 | 13593 | 0.190 |
Why?
|
| Dipeptides | 2 | 2022 | 386 | 0.190 |
Why?
|
| Doxorubicin | 2 | 2006 | 2234 | 0.190 |
Why?
|
| Alkaloids | 1 | 2022 | 192 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2022 | 1197 | 0.180 |
Why?
|
| Stem Cells | 2 | 2011 | 3540 | 0.180 |
Why?
|
| Mice, Nude | 6 | 2010 | 3631 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2001 | 618 | 0.170 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 326 | 0.170 |
Why?
|
| Neoplasms | 6 | 2012 | 22390 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2007 | 2059 | 0.160 |
Why?
|
| Chemokine CXCL12 | 2 | 2011 | 457 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 607 | 0.150 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 381 | 0.150 |
Why?
|
| Bone Marrow Cells | 3 | 2011 | 2414 | 0.140 |
Why?
|
| Relative Biological Effectiveness | 1 | 1999 | 313 | 0.140 |
Why?
|
| Benzylamines | 2 | 2015 | 251 | 0.130 |
Why?
|
| Receptors, CXCR4 | 2 | 2011 | 729 | 0.130 |
Why?
|
| Whole-Body Irradiation | 2 | 2010 | 435 | 0.120 |
Why?
|
| Amidines | 1 | 2015 | 28 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2008 | 1231 | 0.120 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2015 | 59 | 0.120 |
Why?
|
| Cytochromes b5 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Brain Chemistry | 1 | 2018 | 962 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 1539 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 13699 | 0.120 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 272 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 515 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1629 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2001 | 3659 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2008 | 877 | 0.110 |
Why?
|
| Extracellular Space | 3 | 2006 | 566 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 9442 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2007 | 3621 | 0.100 |
Why?
|
| Cell Death | 1 | 1998 | 1682 | 0.100 |
Why?
|
| Prealbumin | 1 | 2014 | 259 | 0.100 |
Why?
|
| Angiotensins | 1 | 2013 | 141 | 0.100 |
Why?
|
| Rectal Neoplasms | 3 | 2006 | 1183 | 0.100 |
Why?
|
| Animals | 23 | 2024 | 169408 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 2565 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 1998 | 1315 | 0.090 |
Why?
|
| Losartan | 1 | 2013 | 262 | 0.090 |
Why?
|
| Receptors, CXCR | 1 | 2011 | 52 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 621 | 0.090 |
Why?
|
| Mice | 14 | 2024 | 82074 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 428 | 0.090 |
Why?
|
| Glioblastoma | 3 | 2004 | 3525 | 0.080 |
Why?
|
| Blood Vessels | 2 | 2005 | 1110 | 0.080 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 915 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2015 | 4148 | 0.070 |
Why?
|
| Collagenases | 1 | 2007 | 221 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 983 | 0.070 |
Why?
|
| Pyridines | 1 | 2018 | 2896 | 0.070 |
Why?
|
| Pregnancy Proteins | 1 | 2007 | 222 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2010 | 840 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2022 | 997 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2006 | 2018 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3724 | 0.060 |
Why?
|
| Receptors, Death Domain | 1 | 2024 | 31 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2007 | 620 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 1769 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2013 | 1762 | 0.050 |
Why?
|
| Veratrum Alkaloids | 1 | 2022 | 23 | 0.050 |
Why?
|
| Humans | 24 | 2024 | 768887 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 2395 | 0.050 |
Why?
|
| Glucose | 2 | 2006 | 4352 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2006 | 664 | 0.050 |
Why?
|
| Radiation Tolerance | 2 | 2001 | 478 | 0.050 |
Why?
|
| Glioma | 2 | 2008 | 3532 | 0.050 |
Why?
|
| Topotecan | 1 | 2001 | 131 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 11229 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2006 | 8559 | 0.050 |
Why?
|
| Proteomics | 1 | 2014 | 3913 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2006 | 2920 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 361 | 0.040 |
Why?
|
| Macrophages | 1 | 2015 | 5800 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2008 | 1970 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 2 | 2014 | 320 | 0.040 |
Why?
|
| Oxygen | 4 | 2008 | 4273 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2149 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 14751 | 0.040 |
Why?
|
| CHO Cells | 2 | 1999 | 1380 | 0.040 |
Why?
|
| Liver | 1 | 2014 | 7579 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2022 | 665 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1999 | 228 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2006 | 3518 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1998 | 148 | 0.040 |
Why?
|
| Drug Stability | 1 | 2018 | 292 | 0.040 |
Why?
|
| Cricetinae | 2 | 1999 | 2423 | 0.040 |
Why?
|
| Cell Division | 2 | 2004 | 4478 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2024 | 3233 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2001 | 505 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 65485 | 0.030 |
Why?
|
| Dopamine | 1 | 2022 | 1617 | 0.030 |
Why?
|
| Immobilized Proteins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5443 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2015 | 144 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2015 | 166 | 0.030 |
Why?
|
| Fluorouracil | 2 | 2013 | 1655 | 0.030 |
Why?
|
| Rats | 2 | 2022 | 23847 | 0.030 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 17174 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 2734 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 2813 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2015 | 8664 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 4428 | 0.030 |
Why?
|
| Protons | 1 | 1999 | 1113 | 0.030 |
Why?
|
| Body Weight | 2 | 2001 | 4628 | 0.030 |
Why?
|
| Male | 9 | 2024 | 365249 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 91 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 40266 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2013 | 153 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2013 | 296 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.020 |
Why?
|
| Drug Repositioning | 1 | 2013 | 245 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3951 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 662 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1169 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2005 | 6401 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 245 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 488 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 21187 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 642 | 0.020 |
Why?
|
| Mice, SCID | 2 | 2004 | 2631 | 0.020 |
Why?
|
| Cell Survival | 1 | 1999 | 5794 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8742 | 0.020 |
Why?
|
| Cattle | 1 | 2014 | 3820 | 0.020 |
Why?
|
| Cytokines | 1 | 2024 | 7453 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5890 | 0.020 |
Why?
|
| Protein Binding | 2 | 2014 | 9344 | 0.020 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2013 | 542 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 1680 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 175 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 3283 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 8200 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 1337 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 2004 | 0.020 |
Why?
|
| Skin | 1 | 2001 | 4507 | 0.020 |
Why?
|
| Homeodomain Proteins | 2 | 2008 | 2431 | 0.020 |
Why?
|
| Ephrin-B2 | 1 | 2004 | 40 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 706 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 11886 | 0.010 |
Why?
|
| Collagen | 1 | 2013 | 2646 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2004 | 125 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18366 | 0.010 |
Why?
|
| Angiopoietin-1 | 1 | 2004 | 134 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 2004 | 182 | 0.010 |
Why?
|
| Hydrostatic Pressure | 1 | 2004 | 99 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2004 | 348 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2004 | 319 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 899 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 254 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4568 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 393 | 0.010 |
Why?
|
| Pericytes | 1 | 2004 | 299 | 0.010 |
Why?
|
| Models, Biological | 2 | 2011 | 9499 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 599 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 809 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1505 | 0.010 |
Why?
|
| Female | 5 | 2015 | 397464 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 705 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2004 | 773 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 20244 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2015 | 23652 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 1687 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 1444 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 2004 | 1086 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4353 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1999 | 201 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 5035 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 16735 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 5763 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 2941 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3811 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 2422 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 2492 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 4926 | 0.010 |
Why?
|
| Biological Transport | 1 | 1999 | 2085 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10778 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 5216 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 3450 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 14485 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12873 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 6334 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 11119 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 8055 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 9528 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5709 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7885 | 0.000 |
Why?
|
| Disease Progression | 1 | 2004 | 13677 | 0.000 |
Why?
|
| Prognosis | 1 | 2005 | 30044 | 0.000 |
Why?
|
| Aged | 1 | 2005 | 171790 | 0.000 |
Why?
|
| Middle Aged | 1 | 2005 | 223740 | 0.000 |
Why?
|